GLP1R and Hypoglycemia: Blockade of the GLP-1 receptor with the antagonist exendin 9–39 (also known by its recommended international non-proprietary name avexitide) leads to the correction of hypoglycaemia and reduced hyperinsulinaemia in response to an MMT or OGTT and reduced hypoglycaemic symptoms in people with PBH (10, 107, 108, 109).